Last updated: September 21, 2026
Cobimetinib fumarate, marketed as Cotellic by Genentech and Roche, is an oral MEK1/2 inhibitor approved for BRAF V600 mutation-positive unresectable or metastatic melanoma in combination with vemurafenib. Its commercial position has weakened as melanoma treatment has shifted toward immunotherapy and competing BRAF/MEK combinations. Roche retains a durable specialty-oncology franchise, but growth is constrained by a mature indication, combination dependence, competitive switching, and eventual generic entry risk.
What is cobimetinib fumarate and how is it used?
Cobimetinib fumarate is the fumarate salt of cobimetinib, a selective inhibitor of MEK1 and MEK2. It is supplied as 20 mg tablets under the brand Cotellic.
| Attribute |
Details |
| Active ingredient |
Cobimetinib fumarate |
| Brand |
Cotellic |
| Drug class |
MEK1/2 inhibitor |
| Standard dose |
60 mg orally once daily for 21 consecutive days followed by 7 days off |
| Approved combination |
Vemurafenib, marketed as Zelboraf |
| Principal indication |
BRAF V600 mutation-positive unresectable or metastatic melanoma |
| Original developer |
Exelixis |
| Commercial rights |
Genentech/Roche |
| FDA approval |
November 10, 2015 |
| Regulatory pathway |
New molecular entity approval under an NDA |
| Biosimilar pathway |
Not applicable; cobimetinib is a small molecule |
The FDA approval was based on the coBRIM study, which showed improved progression-free survival for cobimetinib plus vemurafenib compared with vemurafenib alone in patients with BRAF V600-mutant advanced melanoma.[1]
What is the FDA regulatory status of Cotellic?
Cotellic remains FDA-approved for use with vemurafenib in adults with unresectable or metastatic melanoma whose tumors carry a BRAF V600 mutation. The label requires confirmation of BRAF V600 mutation status using an FDA-approved test or another validated assay.[2]
Cobimetinib does not have a broad monotherapy approval. Its commercial value is linked to vemurafenib, which limits prescribing flexibility compared with BRAF/MEK products that are used in broader treatment sequences or have additional approved indications.
The FDA label carries important safety warnings involving:
- Cardiomyopathy and reduced left ventricular ejection fraction
- Ocular toxicity, including retinal vein occlusion and serous retinopathy
- Hemorrhage
- Hepatotoxicity
- Severe dermatologic reactions
- Rhabdomyolysis
- Embryo-fetal toxicity
These warnings can increase monitoring requirements and influence physician selection in a crowded melanoma market.[2]
How has the cobimetinib market evolved?
Cobimetinib entered the market during a period when BRAF-directed therapy was a central treatment option for BRAF-mutant melanoma. Its initial commercial value came from the coBRIM regimen, which improved disease control over BRAF inhibition alone.
The market later changed for three reasons:
- Immune checkpoint inhibitors became foundational therapies for advanced melanoma.
- Competing BRAF/MEK combinations gained broader clinical adoption.
- Treatment sequencing became more individualized, reducing reliance on any single targeted regimen.
The main competing BRAF/MEK combinations are:
| Regimen |
Companies |
Strategic position |
| Cotellic + Zelboraf |
Roche/Genentech |
Established first-generation BRAF/MEK combination |
| Tafinlar + Mekinist |
Novartis |
Broad melanoma use and substantial clinical familiarity |
| Braftovi + Mektovi |
Pfizer, formerly Array/BioMed Realty |
Strong activity in BRAF-mutant melanoma and colorectal cancer |
| Encorafenib-based combinations |
Pfizer |
Longer half-life and differentiated dosing profile |
| Immunotherapy regimens |
Bristol Myers Squibb, Merck, others |
Major competitive alternative in melanoma sequencing |
Cotellic’s core market is therefore narrower than its original opportunity. The product remains relevant when targeted therapy is selected for BRAF V600-mutant disease, but its dependence on vemurafenib creates a commercial disadvantage against regimens perceived as easier to use or more durable.
What is the financial trajectory for cobimetinib?
Roche does not generally report Cotellic as a major standalone growth product in the same way it reports leading oncology brands such as Tecentriq, Perjeta, or Phesgo. Public disclosures have placed Cotellic in the mature or declining portion of Roche’s oncology portfolio.
The financial trajectory has four phases:
| Period |
Commercial pattern |
| 2015-2017 |
Launch and rapid uptake in BRAF V600-mutant melanoma |
| 2018-2020 |
Mature sales, with pressure from immunotherapy and competing combinations |
| 2021-2023 |
Gradual erosion as melanoma treatment options expanded |
| 2024 onward |
Mature specialty product with declining volume and increasing exposure to generic risk |
Cotellic revenue is not equivalent to cobimetinib economics for Exelixis. Roche commercializes the product, while Exelixis receives economics under its collaboration arrangement. Exelixis has historically disclosed collaboration revenues and royalty streams across multiple products, but Cotellic is not generally presented as a separate high-growth revenue driver in its investor materials.[3]
The key financial characteristics are:
- Revenue is concentrated in oncology.
- Sales are dependent on a genetically defined melanoma population.
- Net pricing is exposed to European reimbursement controls and U.S. payer management.
- The product has limited expansion outside its original melanoma indication.
- Commercial decline is likely to precede loss of market exclusivity because of therapeutic substitution.
Which companies developed and commercialize cobimetinib?
Exelixis discovered and developed cobimetinib before licensing rights to Genentech in 2009. Genentech, a Roche company, led late-stage development and commercialized Cotellic globally in collaboration with Roche affiliates.[4]
The collaboration structure creates a division between:
- Roche and Genentech, which control commercialization, regulatory execution, and marketing;
- Exelixis, which retains economic participation through royalties and collaboration rights;
- Generic manufacturers, which may later challenge listed patents or seek approval after patent expiry.
This structure reduces Exelixis’ direct commercial control. It also means that the product’s strategic value is assessed within Roche’s broader melanoma portfolio rather than as an independent Exelixis franchise.
What patents protect cobimetinib fumarate?
Cobimetinib protection is based primarily on compound, pharmaceutical composition, and method-of-use patents. Representative U.S. patent families associated with cobimetinib include patents directed to substituted pyrimidine compounds and their therapeutic use.
| Patent category |
Protection scope |
Commercial relevance |
| Compound patents |
Cobimetinib chemical structure and related compounds |
Primary exclusivity layer |
| Salt and solid-form patents |
Fumarate salt, crystal form, or related physical properties |
Can complicate formulation-level challenges |
| Composition patents |
Tablets and pharmaceutical compositions containing cobimetinib |
Supports product-specific protection |
| Method-of-use patents |
Treatment of BRAF-mutant melanoma, often with vemurafenib |
May delay or narrow generic substitution |
| Manufacturing patents |
Processes for producing active ingredient or intermediates |
Can increase development costs but rarely blocks all generic entry |
Representative U.S. records associated with the cobimetinib estate include U.S. Patent No. 8,440,863 and related continuation or composition claims. The relevant expiration dates depend on patent-term adjustment, patent-term extension, claim scope, and the specific listing used by an applicant.[5]
The practical protection profile is more important than the number of patents. A strong compound patent can block the active ingredient even where formulation patents are vulnerable. A weak or expired compound patent can leave the originator dependent on narrower formulation or method-of-use claims.
When does cobimetinib lose exclusivity?
Cobimetinib’s regulatory exclusivity has already expired. FDA orphan-drug exclusivity is not the main commercial barrier because the product’s protection depends more heavily on patents and the narrow melanoma indication.
The relevant loss-of-exclusivity sequence is:
| Exclusivity layer |
Status |
| FDA new chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not the principal current barrier |
| Compound patent protection |
Potentially extends into the late 2020s or around 2030, depending on the applicable patent |
| Formulation and method patents |
May extend beyond or overlap with compound protection |
| Generic approval |
Possible after resolution or expiration of relevant listed patents |
A precise generic launch date depends on the latest FDA Orange Book listings, patent-term calculations, Paragraph IV certifications, litigation, and any settlement agreement. A nominal patent expiration does not by itself establish the earliest commercial launch date.
What is the Orange Book status of Cotellic?
Cotellic is listed in the FDA Orange Book as a prescription drug product approved under an NDA. The Orange Book identifies patents that the NDA holder or patent owner represents as covering the drug substance, drug product, or approved method of use.[6]
Orange Book-listed patents can support:
- A Paragraph III certification, deferring launch until patent expiration;
- A Paragraph IV certification, asserting that a listed patent is invalid, unenforceable, or not infringed;
- A 30-month litigation stay if the patent owner files suit within the statutory period;
- Potential market exclusivity for the first substantially complete Paragraph IV filer.
For cobimetinib, the commercial importance of each listing depends on whether it covers the active ingredient itself or only a specific formulation or indication. A generic applicant may avoid a method-of-use patent through a section viii statement and seek approval for a non-patented use, subject to labeling constraints.
Which companies are challenging Cotellic patents?
No broadly reported, market-defining Paragraph IV litigation has established a generic challenger as the central competitive threat to Cotellic. The absence of a prominent public challenge does not eliminate future risk. Generic manufacturers can file abbreviated new drug applications as patent dates approach, particularly where the product has established reimbursement and manufacturing economics.
Potential challengers would likely include large generic companies with oncology capabilities, such as Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy’s Laboratories, and Hikma. The actual commercial threat would depend on:
- Whether the generic targets the 20 mg tablet;
- Whether it challenges compound or formulation claims;
- Whether it uses a carve-out label;
- Whether it obtains a first-filer position;
- Whether Roche or Genentech settles the litigation.
How strong is the cobimetinib patent estate?
The cobimetinib estate is commercially meaningful but not uniformly strong across all claim types.
Strengths
- A defined small-molecule product with an established chemical identity
- A clinically validated indication
- Combination-use claims linked to a specific biomarker-defined population
- Potentially overlapping compound, composition, and method patents
- Manufacturing complexity associated with oncology-grade active pharmaceutical ingredient
Weaknesses
- Regulatory exclusivity has expired
- The principal indication is narrow
- Method-of-use claims may be vulnerable to label carve-outs
- Formulation patents can be designed around
- Generic manufacturers can target the same active ingredient after compound protection ends
- Market decline may reduce the originator’s ability to justify prolonged litigation
Patent strength is therefore moderate rather than absolute. The product may retain meaningful protection into the late 2020s, but the estate is unlikely to prevent all substitution indefinitely once the core compound barrier falls.
What manufacturing and intellectual-property barriers affect generic entry?
Cobimetinib generic development requires control of:
- The active pharmaceutical ingredient and relevant intermediates
- The fumarate salt or approved solid form
- Tablet uniformity at a low-strength dosage
- Dissolution and bioequivalence performance
- Impurity controls
- Stability under commercial packaging conditions
- Oncology manufacturing and quality systems
Manufacturing patents can raise development costs, but they do not necessarily prevent a non-infringing process. The more important barrier is the combination of active-ingredient patent protection and FDA requirements for bioequivalence.
Because Cotellic is an oral tablet rather than a biologic or complex delivery system, generic manufacturing barriers are lower than those for injectable biologics, depot products, or highly complex formulations.
What generic launch scenarios exist for cobimetinib?
Three scenarios are commercially plausible.
At-risk launch
A generic company launches after filing a Paragraph IV certification and before final patent resolution. This creates immediate litigation and potential damages exposure. The strategy is attractive only if the expected market share and margin justify the legal risk.
Negotiated launch
Roche or Genentech reaches a settlement providing an agreed launch date before the last asserted patent expires. This is a common outcome when the originator wants to preserve price and the challenger wants certainty.
Post-expiry launch
Generic entry occurs after expiration of the core compound patent and any commercially relevant listed patents. This is the lowest-risk scenario and would likely produce rapid price erosion if multiple suppliers enter.
The likely market effect is sharper in the United States than in fragmented European markets. U.S. pharmacy benefit managers and specialty distributors can accelerate substitution after multiple generics receive approval.
How does cobimetinib compare with competing MEK inhibitors?
Cobimetinib has a credible clinical profile but a weaker current commercial position than leading combination products with broader labels or stronger treatment momentum.
| Factor |
Cobimetinib |
Tafinlar/Mekinist |
Braftovi/Mektovi |
| Core melanoma use |
BRAF V600-mutant melanoma |
BRAF-mutant melanoma |
BRAF-mutant melanoma |
| Main partner |
Vemurafenib |
Dabrafenib |
Encorafenib |
| Commercial maturity |
Mature |
Mature but broader franchise |
Mature, with additional oncology relevance |
| Expansion potential |
Limited |
Broader development history |
Broader use in colorectal cancer |
| Generic risk |
Increasing |
Increasing |
Increasing |
| Differentiation |
Established coBRIM evidence |
Extensive clinical adoption |
Differentiated pharmacology and broader commercial platform |
Cotellic remains clinically relevant, but its revenue outlook depends more on maintaining a residual targeted-therapy niche than on gaining new market share.
What patent litigation and settlement risks affect Cotellic?
The main litigation risk is a future ANDA case involving an Orange Book-listed compound, composition, or method patent. Key legal issues would include:
- Infringement of cobimetinib compound claims
- Validity of written-description and enablement claims
- Obviousness of the fumarate salt or solid form
- Infringement through a generic tablet formulation
- Use of a skinny label for non-patented indications
- Potential launch under a settlement agreement
A settlement could preserve several years of branded sales while giving the generic applicant a defined entry date. The value of such an agreement would be lower than for a high-growth product because Cotellic’s underlying market is mature and its clinical share is vulnerable to therapeutic substitution.
What is the revenue exposure for Roche and Exelixis?
Cotellic is unlikely to be a material driver of Roche’s consolidated revenue. Its financial importance is greater at the product-franchise level and within Exelixis’ collaboration economics.
For Roche, the principal risks are:
- Continued erosion from treatment substitution
- Reimbursement pressure
- Generic entry after patent expiry
- Reduced use of vemurafenib-based therapy
- Lower physician familiarity relative to newer combinations
For Exelixis, the asset provides royalty and collaboration income but does not carry the strategic weight of newer pipeline or commercial products. A generic launch would reduce the royalty base and could accelerate the decline in collaboration revenue.
Key Takeaways
- Cobimetinib fumarate is marketed as Cotellic and approved with vemurafenib for BRAF V600-mutant advanced melanoma.
- FDA regulatory exclusivity has expired; patent protection is the principal remaining barrier.
- The product’s market has matured as immunotherapy and competing BRAF/MEK combinations gained share.
- Roche controls commercialization, while Exelixis retains collaboration economics.
- The patent estate likely includes compound, composition, method-of-use, and manufacturing claims, with relevant protection extending into the late 2020s or around 2030 depending on the patent.
- No publicly dominant Paragraph IV challenge has defined the current market.
- Generic entry would likely produce substantial price erosion because Cotellic is an oral small molecule with a relatively conventional dosage form.
- The principal commercial risk is gradual therapeutic substitution before formal loss of exclusivity.
FAQs
Is cobimetinib fumarate the same drug as Cotellic?
Yes. Cotellic contains cobimetinib fumarate, the fumarate salt of cobimetinib.
Is cobimetinib a biologic with biosimilar risk?
No. Cobimetinib is a synthetic small molecule. Future competitors would generally use the abbreviated new drug application pathway rather than the biosimilar pathway.
Can a generic company avoid cobimetinib method-of-use patents?
Potentially. A generic applicant may use a section viii statement or a carved-out label for non-patented uses, but the feasibility depends on the scope of the Orange Book-listed claims and the proposed labeling.
Does Cotellic have a combination-product patent?
Cotellic’s protection can include method-of-use claims covering administration with vemurafenib. The enforceability of those claims depends on the precise claim language, approved labeling, and generic product conduct.
Is cobimetinib still commercially important in melanoma?
Yes, but its role is narrower than at launch. It remains an approved targeted option for BRAF V600-mutant melanoma, while immunotherapy and competing BRAF/MEK regimens limit market expansion.
References
-
Food and Drug Administration. (2015). FDA approves cobimetinib with vemurafenib for metastatic melanoma. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Cotellic (cobimetinib) prescribing information. Genentech USA, Inc.
-
Exelixis, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Roche Holding Ltd. (2009). Roche and Exelixis enter worldwide collaboration for cancer compounds. Roche.
-
United States Patent and Trademark Office. (n.d.). U.S. Patent No. 8,440,863 and related cobimetinib patent records. U.S. Department of Commerce.
-
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
